US 2006/0041137 A1Published application

Kinase inhibitors

AssigneeTakeda San Diego, Inc.

InventorsSheldon Cao, Anthony Gangloff, Bheema Paraselli, Jeffrey Stafford, Hasanthi Wijesekera

Life of this patent

Estimating the term…

Abstract

Compounds, pharmaceutical compositions, kits and methods are provided for use with kinases that comprise a compound of the formula: wherein R1, R2, R3, Q, U, V, W, X, and Y are as defined herein.

Claims49

Dependent claims

A compound comprising the formula:

wherein:
R1 is selected from the group consisting of hydrogen or a substituent convertible in vivo to hydrogen;
R2 is selected from the group consisting of hydrogen, (C1-6)alkyl or a substituent convertible in vivo to hydrogen;
R3 is selected from the group consisting of hydrogen, (C1-12)alkyl, alkoxy, thio, hydroxy, (C3-12)cycloalkyl, hetero(C2-12)cycloalkyl, hetero(C2-12)cycloalkoxy, (C9-12)bicycloaryl, hetero(C4-12)bicycloaryl, aryl, heteroaryl, heteroaryloxy, aryloxy, amino, carbonyl, imino, sulfonyl, sulfinyl, halo, cyano, nitro, trifluoromethoxy, and aryl(C1-12)alkyl, each unsubstituted or substituted, with the proviso that R3 is not hetero(C2-12)cycloalkyl, hetero(C4-12)bicycloaryl, or heteroaryl when Q is CO;
Q is selected from the group consisting of CO, CS, and C═NR4;
U is selected from the group consisting of CR5 or N;
V is selected from the group consisting of CR6 or N;
W is selected from the group consisting of CR7 or N;
X is selected from the group consisting of CR8 or N;
Y is selected from the group consisting of CR9 or N;
Z is selected from the group consisting of CR10 or N;
R4 is selected from the group consisting of hydrogen and unsubstituted or substituted (C1-3)alkyl;
R5 and R6 are each independently selected from the group consisting of hydrogen, halo, halo(C1-10)alkyl, amino, nitro, cyano, thio, sulfonamide, (C1-10)alkyl, (C3-12)cycloalkyl, hetero(C2-12)cycloalkyl, aryl(C1-10)alkyl, heteroaryl(C1-5)alkyl, (C9-12)bicycloaryl, hetero(C4-12)bicycloaryl, carbonyl(C1-3)alkyl, thiocarbonyl(C1-3)alkyl, sulfonyl(C1-3)alkyl, sulfinyl(C1-3)alkyl, imino(C1-3)alkyl, (C1-10)alkylamino, amino (C1-10)alkyl, aryl, heteroaryl, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, imino, sulfonyl, and sulfinyl, each unsubstituted or substituted, or R5 and R6 are taken together to form an unsubstituted or substituted ring;
and
R7, R8, R9, and R10 are each independently selected from the group consisting of hydrogen, halo, halo(C1—I0)alkyl, amino, nitro, cyano, thio, sulfonamide, (C1-10)alkyl, (C3-12)cycloalkyl, hetero(C2-12)cycloalkyl, aryl(C1-10)alkyl, heteroaryl(C1-5)alkyl, (C9-12)bicycloaryl, hetero(C4-12)bicycloaryl, carbonyl(C1-3)alkyl, thiocarbonyl(C1-3)alkyl, sulfonyl(C1-3)alkyl, sulfinyl(C1-3)alkyl, imino(C1-3)alkyl, aryl, heteroaryl, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl group, imino group, sulfonyl group and sulfinyl group, each unsubstituted or substituted, or R6 and R7, R7 and R8, R8 and R9, R9 and R10, or R10 and R1 are taken together to form an unsubstituted or substituted ring.

12 more elements

A compound selected from the group consisting of:

(Z)-3-methyl-4-(quinolin-2(1H)-ylidene)-1H-pyrazol-5(4H)-one;
(Z)-4-(4-chloroquinolin-2(1H)-ylidene)-3-methyl-1H-pyrazol-5(4H)-one;
(Z)-4-(6-(2-(dimethylamino)ethoxy)quinolin-2(1H)-ylidene)-3-methyl-1H-pyrazol-5(4H)-one;
(Z)-4-(4-(6-aminopyridin-3-ylaniino)quinolin-2(1H)-ylidene)-3-methyl-1H-pyrazol-5(4H)-one;
(Z)-4-(4-ethoxyquinolin-2(1H)-ylidene)-3-methyl-1H-pyrazol-5(4H)-one;
(Z)-3-methyl-4-(4-(phenylthio)quinolin-2(1H)-ylidene)-1H-pyrazol-5(4H)-one;
(Z)-4-(4-(4-aminophenylthio)quinolin-2(1H)-ylidene)-3-methyl-1H-pyrazol-5(4H)-one;
(Z)-N-(4-(2-(3-methyl-5-oxo-1H-pyrazol-4(5H)-ylidene)-1,2-dihydroquinolin-4-ylthio)phenyl)acetamide;
(Z)-3-methyl-4-(4-(pyridin-2-ylthio)quinolin-2(1H)-ylidene)-1H-pyrazol-5(4H)-one;
(Z)-6-(2-(3-methyl-5-oxo-1H-pyrazol-4(5H)-ylidene)-1,2-dihydroquinolin-4-ylthio)nicotinic acid;
(Z)-N-(4-(2-(3-methyl-5-oxo-1H-pyrazol-4(5H)-ylidene)-1,2-dihydroquinolin-4-ylthio)phenyl)cyclopropanecarboxamide;
(Z)-4-(4-chloroquinolin-2(1H)-ylidene)-3-ethyl-1H-pyrazol-5(4H)-one;
(Z)-N-(4-(2-(3-ethyl-5-oxo-1H-pyrazol-4(5H)-ylidene)-1,2-dihydroquinolin-4-ylthio)phenyl)acetamide;
(Z)-N-(4-(2-(3-cyclopropyl-5-oxo-1H-pyrazol-4(5H)-ylidene)-1,2-dihydroquinolin-4-ylthio)phenyl)acetamide;
(Z)-4-(4-(4-aminophenylthio)quinolin-2(1H)-ylidene)-3-cyclopropyl-1H-pyrazol-5(4H)-one;
(Z)-N-(4-(2-(3-cyclopropyl-5-oxo-1H-pyrazol-4(5H)-ylidene)-1,2-dihydroquinolin-4-ylthio)phenyl)cyclopropanecarboxamide;
(Z)-3-methyl-4-(4-(pyridin-2-ylthio)quinolin-2(1H)-ylidene)-1H-pyrazol-5(4H)-one;
(Z)-3-methyl-4-(4-(pyridin-2-ylthio)quinolin-2(1H)-ylidene)-1H-pyrazol-5(4H)-one;
(Z)-4-(4-chloroquinolin-2(1H)-ylidene)-3-isopropyl-1H-pyrazol-5(4H)-one;
(Z)-N-(4-(2-(3-isopropyl-5-oxo-1H-pyrazol-4(5H)-ylidene)-1,2-dihydroquinolin-4-ylthio)phenyl)acetamide;
(Z)-4-(4-(4-aminophenylthio)quinolin-2(1H)-ylidene)-3-isopropyl-1H-pyrazol-5(4H)-one;
(Z)-N-(4-(2-(3-isopropyl-5-oxo-1H-pyrazol-4(5H)-ylidene)-1,2-dihydroquinolin-4-ylthio)phenyl)methanesulfonamide;
(Z)-N-(4-(2-(3-isopropyl-5-oxo-1H-pyrazol-4(5H)-ylidene)-1,2-dihydroquinolin-4-ylthio)phenyl)ethanesulfonamide;
(Z)-4-(4-chloroquinolin-2(1H)-ylidene)-3-propyl-1H-pyrazol-5(4H)-one;
(Z)-N-(4-(2-(5-oxo-3-propyl-1H-pyrazol-4(5H)-ylidene)-1,2-dihydroquinolin-4-ylthio)phenyl)acetamide;
(Z)-4-(4-(4-aminophenylthio)quinolin-2(1H)-ylidene)-3-propyl-1H-pyrazol-5(4H)-one;
(Z)-N-(4-(2-(5-oxo-3-propyl-1H-pyrazol-4(5H)-ylidene)-1,2-dihydroquinolin-4-ylthio)phenyl)methanesulfonamide;
(Z)-N-(4-(2-(5-oxo-3-propyl-1H-pyrazol-4(5H)-ylidene)-1,2-dihydroquinolin-4-ylthio)phenyl)ethanesulfonamide;
(Z)-2-(dimethylamino)-N-(4-(2-(5-oxo-3-propyl-1H-pyrazol-4(5H)-ylidene)-1,2-dihydroquinolin-4-ylthio)phenyl)acetamide;
(Z)-N-(4-(2-(5-oxo-3-propyl-1H-pyrazol-4(5H)-ylidene)-1,2-dihydroquinolin-4-ylthio)phenyl)benzamide;
(Z)-N-(4-(2-(5-oxo-3-propyl-1H-pyrazol-4(5H)-ylidene)-1,2-dihydroquinolin-4-ylthio)phenyl)cyclobutanecarboxamide;
(Z)-N-(4-(2-(5-oxo-3-propyl-1H-pyrazol-4(5H)-ylidene)-1,2-dihydroquinolin-4-ylthio)phenyl)cyclopentanecarboxamide;
(Z)-N-(4-(2-(5-oxo-3-propyl-1H-pyrazol-4(5H)-ylidene)-1,2-dihydroquinolin-4-ylthio)phenyl)furan-2-carboxamide;
(Z)-N-(4-(2-(5-oxo-3-propyl-1H-pyrazol-4(5H)-ylidene)-1,2-dihydroquinolin-4-ylthio)phenyl)thiophene-2-carboxamide;
(Z)-2-methoxy-N-(4-(2-(5-oxo-3-propyl-1H-pyrazol-4(5H)-ylidene)-1,2-dihydroquinolin-4-ylthio)phenyl)acetamide;
(Z)-N-(4-(2-(5-oxo-3-propyl-1H-pyrazol-4(5H)-ylidene)-1,2-dihydroquinolin-4-ylthio)phenyl)propionamide;
(Z)-N-(4-(2-(5-oxo-3-propyl-1H-pyrazol-4(5H)-ylidene)-1,2-dihydroquinolin-4-ylthio)phenyl)butyramide;
(Z)-N-(4-(2-(5-oxo-3-propyl-1H-pyrazol-4(5H)-ylidene)-1,2-dihydroquinolin-4-ylthio)phenyl)cyclopropanecarboxamide;
(Z)-2-methoxyethyl 4-(2-(5-oxo-3-propyl-1H-pyrazol-4(5H)-ylidene)-1,2-dihydroquinolin-4-ylthio)phenylcarbamate;
(Z)-3-(methylthio)-N-(4-(2-(5-oxo-3-propyl-1H-pyrazol-4(5H)-ylidene)-1,2-dihydroquinolin-4-ylthio)phenyl)propanamide;
(Z)-4-(dimethylamino)-N-(4-(2-(5-oxo-3-propyl-1H-pyrazol-4(5H)-ylidene)-1,2-dihydroquinolin-4-ylthio)phenyl)butanamide;
(Z)-3-(diethylamino)-N-(4-(2-(5-oxo-3-propyl-1H-pyrazol-4(5H)-ylidene)-1,2-dihydroquinolin-4-ylthio)phenyl)propanamide;
(Z)-N-(4-(2-(5-oxo-3-propyl-1H-pyrazol-4(5H)-ylidene)-1,2-dihydroquinolin-4-ylthio)phenyl)isobutyramide;
(R,Z)-1-methyl-N-(4-(2-(5-oxo-3-propyl-1H-pyrazol-4(5H)-ylidene)-1,2-dihydroquinolin-4-ylthio)phenyl)pyrrolidine-2-carboxamide;
(Z)-1-methyl-N-(4-(2-(5-oxo-3-propyl-1H-pyrazol-4(5H)-ylidene)-1,2-dihydroquinolin-4-ylthio)phenyl)piperidine-4-carboxamide;
(Z)-N-(4-(6-methoxy-2-(5-oxo-3-propyl-1H-pyrazol-4(5H)-ylidene)-1,2-dihydroquinolin-4-ylthio)phenyl)acetamide;
(Z)-4-(4-(4-aminophenylthio)-6-methoxyquinolin-2(1H)-ylidene)-3-propyl-1H-pyrazol-5(4H)-one;
(Z)-N-(4-(2-(3-cyclopropyl-5-oxo-1H-pyrazol-4(5H)-ylidene)-6-methoxy-1,2-dihydroquinolin-4-ylthio)phenyl)acetamide;
(Z)-N-(4-(2-(3-cyclohexyl-5-oxo-1H-pyrazol-4(5H)-ylidene)-1,2-dihydroquinolin-4-ylthio)phenyl)acetamide;
(Z)-4-(4-(4-aminophenylthio)quinolin-2(1H)-ylidene)-3-cyclohexyl-1H-pyrazol-5(4H)-one;
(Z)-N-(4-(2-(5-oxo-3-propyl-1H-pyrazol-4(5H)-ylidene)-1,2-dihydroquinolin-4-ylsulfonyl)phenyl)propionamide;
(Z)-5-(2-(5-oxo-3-propyl-1H-pyrazol-4(5H)-ylidene)-1,2-dihydroquinolin-4-ylamino)-1H-indazol-3(2H)-one;
(Z)-N-(4-((5-oxo-4-(quinolin-2(1H)-ylidene)-4,5-dihydro-1H-pyrazol-3-yl)methyl)phenyl)methanesulfonamide;
(Z)-3-phenyl-4-(quinolin-2(1H)-ylidene)-1H-pyrazol-5(4H)-one;
(Z)-N-methyl-4-(5-oxo-4-(quinolin-2(1H)-ylidene)-4,5-dihydro-1H-pyrazol-3-yl)benzenesulfonamide;
(Z)-3-cyclopropyl-4-(isoquinolin-1(2H)-ylidene)-1H-pyrazol-5(4H)-one;
(Z)-N-(4-(2-(1-methyl-5-oxo-3-propyl-1H-pyrazol-4(5H)-ylidene)-1,2-dihydroquinolin-4-ylthio)phenyl)acetamide;
(Z)-N-(3-(2-(5-oxo-3-propyl-1H-pyrazol-4(5H)-ylidene)-1,2-dihydroquinolin-4-yl)phenyl)methanesulfonamide;
(Z)-3-amino-4-(quinolin-2(1H)-ylidene)-1H-pyrazol-5(4H)-one;
((Z)-N-(4-(2-(3-methyl-5-oxo-1H-pyrazol-4(5H)-ylidene)-1,2-dihydroquinolin-4-ylthio)phenyl)methanesulfonamide;
(Z)-3-benzyl-4-(quinolin-2(1H)-ylidene)-1H-pyrazol-5(4H)-one;
(Z)-3-benzyl-4-(4-chloroquinolin-2(1H)-ylidene)-1H-pyrazol-5(4H)-one;
(Z)-3-benzyl-4-(4-phenylthio)quinolin-2(1H)-ylidene)-1H-pyrazol-5(4H)-one;
(Z)-4-(4-(4-aminophenylthio)quinolin-2(1H)-ylidene)-3-methyl-1H-pyrazol-5(4H)-one;
(Z)-N-(4-(2-(3-benzyl-5-oxo-1H-pyrazol-4(5H)-ylidene)-1,2-dihydroquinolin-4-ylthio)phenyl)acetamide;
(Z)-4-(4-(2-methoxyphenylthio)quinolin-2(1H)-ylidene)-3-methyl-1H-pyrazol-5(4H)-one;
(Z)-3-methyl-4-(4-(m-tolylthio)quinolin-2(1H)-ylidene)-1H-pyrazol-5(4H)-one;
(Z)-methyl 3-(2-(3-methyl-5-oxo-1H-pyrazol-4(5H)-ylidene)-1,2-dihydroquinolin-4-ylthio)benzoate;
(Z)-methyl 2-(2-(3-methyl-5-oxo-1H-pyrazol-4(5H)-ylidene)-1,2-dihydroquinolin-4-ylthio)benzoate;
(Z)-3-methyl-4-(4-(o-tolylthio)quinolin-2(1H)-ylidene)-1H-pyrazol-5(4H)-one;
(Z)-methyl 3-(2-(3-methyl-5-oxo-1H-pyrazol-4(5H)-ylidene)-1,2-dihydroquinolin-4-ylthio)benzoic acid;
(Z)-3-methyl-4-(4-(4-nitrophenyl)quinolin-2(1H)-ylidene)-1H-pyrazol-5(4H)-one;
(Z)-4-(4-(2-hydroxyphenylthio)quinolin-2(1H)-ylidene)-1H-pyrazol-5(4H)-one;
3-cyclopropyl-4-(quinolin-2(1H)-ylidene)-1H-pyrazol-5(4H)-one;
4-(4-chloroquinolin-2(1H)-ylidene)-3-cyclopropyl-1H-pyrazol-5(4H)-one;
3-((Z)-5-oxo-4-(quinolin-2(1H)-ylidene)-4,5-dihydro-1H-pyrazol-3-yl)acrylamide;
3-(5-oxo-4-(quinolin-2(1H)-ylidene)-4,5-dihydro-1H-pyrazol-3-yl)propanamide;
2-(5-oxo-4-(quinolin-2(1H)-ylidene)-4,5-dihydro-1H-pyrazol-3-yl)cyclopropanecarboxamide;
N-methyl-2-(5-oxo-4-(quinolin-2(1H)-ylidene)-4,5-dihydro-1H-pyrazol-3-yl)cyclopropane-1-sulfonamide;
3-(4-aminobenzyl)-4-(quinolin-2(1H)-ylidene)-1H-pyrazol-5(4H)-one;
3-(4-aminophenylamino)-4-(quinolin-2(1H)-ylidene)-1H-pyrazol-5 (4H)-one;
3-(4-aminophenylthio)-4-(quinolin-2(1H)-ylidene)-1H-pyrazol-5(4H)-one;
N-(4-((5-oxo-4-(quinolin-2(1H)-ylidene)-4,5-dihydro-1H-pyrazol-3-yl)methyl)phenyl)acetamide;
N-(4-(5-oxo-4-(quinolin-2(1H)-ylidene)-4,5-dihydro-1H-pyrazol-3-ylamino)phenyl)acetamide;
N-(4-(5-oxo-4-(quinolin-2(1H)-ylidene)-4,5-dihydro-1H-pyrazol-3-ylthio)phenyl)acetamide;
3-amino-4-(quinolin-2(1H)-ylidene)-1H-pyrazol-5(4H)-one;
N-(5-oxo-4-(quinolin-2(1H)-ylidene)-4,5-dihydro-1H-pyrazol-3-yl)acetamide;
1-methyl-3-(5-oxo-4-(quinolin-2(1H)-ylidene)-4,5-dihydro-1H-pyrazol-3-yl)urea;
1-(5-oxo-4-(quinolin-2(1H)-ylidene)-4,5-dihydro-1H-pyrazol-3-yl)-3-phenylurea;
2-(4-(6-(2-(dimethylamino)ethoxy)quinolin-2(1H)-ylidene)-5-oxo-4,5-dihydro-1H-pyrazol-3-yl)-N-methylcyclopropane-1-sulfonamide;
2-(4-(6-(2-(diethylamino)ethoxy)quinolin-2(1H)-ylidene)-5-oxo-4,5-dihydro-1H-pyrazol-3-yl)-N-methylcyclopropane-1-sulfonamide;
N-methyl-4-(2-(3-methyl-5-oxo-1H-pyrazol-4(5H)-ylidene)-1,2-dihydroquinolin-4-ylthio)benzenesulfonamide;
(Z)-3-(2-(ethylsulfonyl)cyclopropyl)-4-(quinolin-2(1H)-ylidene)-1H-pyrazol-5(4H)-one;
(Z)-4-(6-(2-(dimethylamino)ethoxy)quinolin-2(1H)-ylidene)-3-(2-(ethylsulfonyl)cyclopropyl)-1H-pyrazol-5(4H)-one;
(Z)-N-(5-oxo-4-(quinolin-2(1H)-ylidene)-4,5-dihydro-1H-pyrazol-3-yl)benzamide;
(Z)-3-(ethylsulfonyl)-N-(5-oxo-4-(quinolin-2(1H)-ylidene)-4,5-dihydro-1H-pyrazol-3-yl)benzamide;
(Z)-4-(4-(3-(ethylsulfonyl)phenyl)quinolin-2(1H)-ylidene)-3-methyl-1H-pyrazol-5(4H)-one;
(Z)-4-(4-(1-(ethylsulfonyl)-1H-indol-4-yl)quinolin-2(1H)-ylidene)-3-methyl-1H-pyrazol-5(4H)-one;
(Z)-2-((3-(2-(3-methyl-5-oxo-1H-pyrazol-4(5H)-ylidene)-1,2-dihydroquinolin-4-yl)-1H-pyrazol-1-yl)methyl)benzonitrile;
(Z)-2-((4-(2-(3-methyl-5-oxo-1H-pyrazol-4(5H)-ylidene)-1,2-dihydroquinolin-4-yl)thiazol-2-yl)methyl)benzonitrile;
(Z)-2-((2-(2-(3-methyl-5-oxo-1H-pyrazol-4(5H)-ylidene)-1,2-dihydroquinolin-4-yl)thiazol-4-yl)methyl)benzonitrile;
(Z)-2-((2-(2-(3-methyl-5-oxo-1H-pyrazol-4(5H)-ylidene)-1,2-dihydroquinolin-4-yl)thiazol-5-yl)methyl)benzonitrile;
(Z)-2-((5-(2-(3-methyl-5-oxo-1H-pyrazol-4(5H)-ylidene)-1,2-dihydroquinolin-4-yl)thiazol-2-yl)methyl)benzonitrile;
(Z)-N-(4-(2-(3-methyl-5-oxo-1H-pyrazol-4(5H)-ylidene)-1,2-dihydroquinoline-4-carbonyl)phenyl)cyclopropanecarboxamide;
(Z)-N-(4-((2-(3-methyl-5-oxo-1H-pyrazol-4(5H)-ylidene)-1,2-dihydroquinolin-4-yl)methyl)phenyl)cyclopropanecarboxamide;
(Z)-N-(2-ethyl-4-(2-(3-methyl-5-oxo-1H-pyrazol-4(5H)-ylidene)-1,2-dihydroquinolin-4-ylthio)phenyl)cyclopropanecarboxamide;
(Z)-N-(2-methoxy-4-(2-(3-methyl-5-oxo-1H-pyrazol-4(5H)-ylidene)-1,2-dihydroquinolin-4-ylthio)phenyl)cyclopropanecarboxamide;
(Z)-3-(4-(ethylsulfonyl)phenyl)-4-(quinolin-2(1H)-ylidene)-1H-pyrazol-5(4H)-one;
(Z)-3-(3-(ethylsulfonyl)phenyl)-4-(quinolin-2(1H)-ylidene)-1H-pyrazol-5(4H)-one;
(Z)-3-(1-(ethylsulfonyl)-1H-indol-5-yl)-4-(quinolin-2(1H)-ylidene)-1H-pyrazol-5(4H)-one;
(Z)-N-cyclopropyl-2-(5-oxo-4-(quinolin-2(1H)-ylidene)-4,5-dihydro-1H-pyrazol-3-yl)thiazole-5-carboxamide;
and
(Z)-N-(2-(5-oxo-4-(quinolin-2(1H)-ylidene)-4,5-dihydro-1H-pyrazol-3-yl)thiazol-5-yl)cyclopropanecarboxamide.

110 more elements

Dependencies are inferred from the claim text.

Facts

Application: 11/208,437Filed 18 Aug 2005
Priority: 18 Aug 2004
Published: 23 Feb 2006
Term ends: Not estimatedThe source records don’t support an estimate.

Classification18 codes

C07D 401/04
Containing two hetero rings: directly linked by a ring-member-to-ring-member bond
A61P 1/04
Drugs for disorders of the alimentary tract or the digestive system: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of…
A61P 17/06
Drugs for dermatological disorders: antipsoriatics
A61P 25/00
Drugs for disorders of the nervous system

Family

Application60/602,902Us provisional application · filed 18 Aug 2004
US 7,550,598 B2Related patent
US 2006/0041137 A1This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

Building an agent or pulling many patents? Use the API or MCP server instead of scraping pages. Get an API key

patentgrep

Loading patent…

Abstract

Compounds, pharmaceutical compositions, kits and methods are provided for use with kinases that comprise a compound of the formula: wherein R1, R2, R3, Q, U, V, W, X, and Y are as defined herein.

A compound comprising the formula:

wherein:
R1 is selected from the group consisting of hydrogen or a substituent convertible in vivo to hydrogen;
R2 is selected from the group consisting of hydrogen, (C1-6)alkyl or a substituent convertible in vivo to hydrogen;
R3 is selected from the group consisting of hydrogen, (C1-12)alkyl, alkoxy, thio, hydroxy, (C3-12)cycloalkyl, hetero(C2-12)cycloalkyl, hetero(C2-12)cycloalkoxy, (C9-12)bicycloaryl, hetero(C4-12)bicycloaryl, aryl, heteroaryl, heteroaryloxy, aryloxy, amino, carbonyl, imino, sulfonyl, sulfinyl, halo, cyano, nitro, trifluoromethoxy, and aryl(C1-12)alkyl, each unsubstituted or substituted, with the proviso that R3 is not hetero(C2-12)cycloalkyl, hetero(C4-12)bicycloaryl, or heteroaryl when Q is CO;
Q is selected from the group consisting of CO, CS, and C═NR4;
U is selected from the group consisting of CR5 or N;
V is selected from the group consisting of CR6 or N;
W is selected from the group consisting of CR7 or N;
X is selected from the group consisting of CR8 or N;
Y is selected from the group consisting of CR9 or N;
Z is selected from the group consisting of CR10 or N;
R4 is selected from the group consisting of hydrogen and unsubstituted or substituted (C1-3)alkyl;
R5 and R6 are each independently selected from the group consisting of hydrogen, halo, halo(C1-10)alkyl, amino, nitro, cyano, thio, sulfonamide, (C1-10)alkyl, (C3-12)cycloalkyl, hetero(C2-12)cycloalkyl, aryl(C1-10)alkyl, heteroaryl(C1-5)alkyl, (C9-12)bicycloaryl, hetero(C4-12)bicycloaryl, carbonyl(C1-3)alkyl, thiocarbonyl(C1-3)alkyl, sulfonyl(C1-3)alkyl, sulfinyl(C1-3)alkyl, imino(C1-3)alkyl, (C1-10)alkylamino, amino (C1-10)alkyl, aryl, heteroaryl, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, imino, sulfonyl, and sulfinyl, each unsubstituted or substituted, or R5 and R6 are taken together to form an unsubstituted or substituted ring;
and
R7, R8, R9, and R10 are each independently selected from the group consisting of hydrogen, halo, halo(C1—I0)alkyl, amino, nitro, cyano, thio, sulfonamide, (C1-10)alkyl, (C3-12)cycloalkyl, hetero(C2-12)cycloalkyl, aryl(C1-10)alkyl, heteroaryl(C1-5)alkyl, (C9-12)bicycloaryl, hetero(C4-12)bicycloaryl, carbonyl(C1-3)alkyl, thiocarbonyl(C1-3)alkyl, sulfonyl(C1-3)alkyl, sulfinyl(C1-3)alkyl, imino(C1-3)alkyl, aryl, heteroaryl, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl group, imino group, sulfonyl group and sulfinyl group, each unsubstituted or substituted, or R6 and R7, R7 and R8, R8 and R9, R9 and R10, or R10 and R1 are taken together to form an unsubstituted or substituted ring.

12 more elements

Facts

Application

11/208,437Filed 18 Aug 2005

Priority

18 Aug 2004

Published

23 Feb 2006

Term ends

Not estimatedThe source records don’t support an estimate.

Classification18 codes

C07D 401/04
Containing two hetero rings: directly linked by a ring-member-to-ring-member bond
A61P 1/04
Drugs for disorders of the alimentary tract or the digestive system: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of…
A61P 17/06
Drugs for dermatological disorders: antipsoriatics
A61P 25/00
Drugs for disorders of the nervous system